Every Form 4 that Theravance Biopharma, Inc. (TBPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TBPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TBPH filings page.
Theravance Biopharma, Inc. (TBPH) reported that Chief Executive Officer and director Rick E. Winningham had 20,034 Ordinary Shares withheld on 2026-08-20 at $16.95 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. The transaction was with the issuer and did not involve an open market trade. Following this tax-withholding disposition, he held 1,611,022 Ordinary Shares directly, plus 23,400 Ordinary Shares held indirectly as custodian and 92,567 Ordinary Shares held indirectly by a trust.
Theravance Biopharma, Inc. (TBPH) reported that its SVP & Chief Financial Officer, Aziz Sawaf, had 8,112 Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations arising from the vesting of previously granted restricted stock units. The shares were withheld by the issuer and did not involve an open market transaction. Following this tax-withholding event, Sawaf directly holds 336,841 Ordinary Shares.
Theravance Biopharma, Inc. (TBPH) reported that officer Aine Miller, SVP, DEV & HEAD OF IRE OFFICE, had 6,258 Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations from the vesting of previously granted restricted stock units. The shares were withheld by the issuer, not sold in an open market transaction, leaving Miller with 189,826 Ordinary Shares held directly after the transaction.
Theravance Biopharma, Inc. (TBPH) reported that officer Brett A. Grimaud, SVP, General Counsel and Secretary, had 7,952 Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations arising from the vesting of previously granted restricted stock units. The shares were withheld by the issuer at a reference value of $16.95 per share and the transaction did not involve an open market trade. Following this tax-withholding disposition, Grimaud directly holds 355,168 Ordinary Shares of Theravance Biopharma, Inc.
Theravance Biopharma, Inc. (TBPH) reported that officer Rhonda Farnum, SVP, Commercial & Medical Affairs, had 5,667 Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations from the vesting of previously granted restricted stock units. The withholding was with the issuer and did not involve an open market transaction, leaving her with 226,790 shares held directly.
Theravance Biopharma, Inc. insider filings show that funds managed by Madison Avenue Partners, LP, an entity associated with reporting person Eli Samaha, executed open-market sales of common stock over three days. The funds sold 273,871 shares on June 29, 2026 at a weighted average price of about $17.23 per share, 25,027 shares on June 30, 2026 at about $17.13 per share, and 37,799 shares on July 1, 2026 at about $17.00 per share. After these transactions, the filings report that entities managed by Madison Avenue Partners, LP indirectly held 9,174,453 shares of Theravance Biopharma common stock. The footnotes state that Samaha is the managing partner of Madison Avenue Partners, LP and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Miller Aine reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that senior vice president Aine Miller received a grant of 18,750 Ordinary Shares on June 19, 2026. The award was recorded at a price of $0.0000 per share, reflecting a compensation-related grant rather than a market purchase. Following this transaction, Miller directly holds 196,084 Ordinary Shares of Theravance Biopharma.
Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported selling ordinary shares in open-market transactions. On June 15, 2026, she sold a total of 13,314 ordinary shares of Theravance Biopharma in three separate trades.
The reported sale prices were around the mid‑$16 range per share, with individual weighted-average prices of $16.3856, $16.3838 and $16.3902. A footnote explains that these transactions were executed in multiple trades between $16.21 and $16.61 per share, and the prices disclosed reflect the weighted-average sale prices across those trades.
Theravance Biopharma director Laurie Smaldone Alsup received new equity compensation in the form of shares and options. On 2026-06-12, she was granted 6,009 Ordinary Shares at no cost, increasing her direct holdings to 80,989 shares.
On the same date, she was also granted a Share Option covering 13,398 Ordinary Shares at an exercise price of $16.6400 per share, expiring on 2036-06-11. According to the vesting terms, 1/12 of the option vests after each month of continuous service following the grant date, with any remaining unvested portion vesting on the date of the next annual shareholder meeting, subject to continued service.
Theravance Biopharma director Susannah Gray received equity compensation in the form of shares and options. On June 12, 2026, she was granted 6,009 Ordinary Shares, bringing her direct holdings to 48,146 Ordinary Shares after the award.
On the same date, she also received a share option for 13,398 Ordinary Shares at an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option vests after each completed month of continuous service following the grant date, and any remaining unvested portion vests on the date of the next annual shareholder meeting if she remains in continuous service.
Theravance Biopharma director Dean J. Mitchell received equity compensation, gaining 6,009 ordinary shares and a grant of options for 13,398 ordinary shares. The options have an exercise price of $16.64 per share and vest monthly, with remaining unvested options vesting by the next annual shareholder meeting if service continues.
Theravance Biopharma director Donal O'Connor received new equity awards. On June 12, 2026, he was granted 6,009 Ordinary Shares at no cost, increasing his direct holdings to 80,213 Ordinary Shares.
He was also granted a share option for 13,398 Ordinary Shares at an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option shares vest after each continuous month of service following the grant date, with any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders, provided he remains in continuous service.
Theravance Biopharma director Deepika Pakianathan received new equity compensation awards. On June 12, 2026, she acquired 6,009 Ordinary Shares at a price of $0.00 per share, increasing her direct holdings to 64,074 Ordinary Shares.
On the same date, she was also granted a Share Option (Right to Buy) covering 13,398 Ordinary Shares with an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option vests after each month of continuous service following the grant, with remaining unvested shares vesting on the date of the next annual shareholders’ meeting if service continues.
Theravance Biopharma, Inc. chief executive officer Rick E. Winningham reported a routine tax-related share withholding. On May 20, 2026, 20,038 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations from vesting restricted stock units, in a transaction with the company rather than in the open market.
After this withholding, he directly held 1,631,056 Ordinary Shares. He also reported indirect holdings of 92,567 Ordinary Shares held by a trust and 23,400 Ordinary Shares held as custodian.
Theravance Biopharma, Inc. reported that SVP & Chief Financial Officer Aziz Sawaf had 8,670 Ordinary Shares withheld at a price of $16.55 per share to cover tax obligations from vesting restricted stock units. This was a share withholding with the company, not an open market trade. After this routine tax-withholding transaction, Sawaf directly holds 344,953 Ordinary Shares.
Theravance Biopharma SVP Aine Miller reported a routine tax-withholding transaction related to equity compensation. On the vesting of previously granted restricted stock units, 6,827 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations in a transaction with the issuer, not the open market. After this withholding, Miller directly holds 177,334 Ordinary Shares.
Theravance Biopharma SVP Brett A. Grimaud had 8,829 Ordinary Shares withheld at $16.55 per share to cover taxes on vested restricted stock units. The shares were withheld by the company, not sold in the open market. After this tax-withholding transaction, he directly holds 363,120 Ordinary Shares.
Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a routine tax-withholding share disposition tied to equity compensation. On the vesting of previously granted restricted stock units, 5,678 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations. The shares were withheld by the company and did not involve any open-market transaction. After this non-market disposition, Farnum directly holds 245,771 Ordinary Shares, indicating she retains a substantial equity stake following the tax payment event.
Theravance Biopharma CEO Rick E. Winningham received an equity grant of 75,000 Ordinary Shares at no cost. The award was recorded as a grant or other acquisition on Ordinary Shares.
Following this grant, he directly holds 1,651,094 Ordinary Shares and also reports indirect holdings of 23,400 shares as custodian and 92,567 shares held by a trust.
Sawaf Aziz reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that its SVP & Chief Financial Officer, Aziz Sawaf, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share, reflecting compensation rather than a market purchase.
Following this award, Mr. Sawaf directly holds 353,623 Ordinary Shares of Theravance Biopharma. This filing records a stock-based compensation grant to a senior executive, not an open-market buy or sell transaction.
Grimaud Brett A. reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. executive Brett A. Grimaud, SVP, General Counsel and Secretary, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share as compensation rather than a market purchase. Following this grant, his direct holdings increased to 371,949 Ordinary Shares, according to the filing.
Farnum Rhonda reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that SVP, Commercial & Medical Affairs Rhonda Farnum received a grant of 18,750 Ordinary Shares of the company on April 1, 2026. The shares were granted at a stated price of $0.00 per share as compensation rather than a market purchase.
Following this award, Farnum directly holds a total of 251,449 Ordinary Shares of Theravance Biopharma, Inc., reflecting an increase in her equity-based compensation stake in the company.
Theravance Biopharma, Inc. senior executive Rhonda Farnum, SVP, Commercial & Medical Affairs, sold a total of 31,067 ordinary shares of TBPH in open-market transactions on March 16, 2026, at prices ranging from $13.755 to $14.01. After these sales, she directly owns 232,699 ordinary shares of the company.
Theravance Biopharma, Inc. reported an insider equity transaction by Chief Executive Officer Rick E. Winningham. On the reported date, 74,975 ordinary shares were withheld at an implied price of $19.66 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. This withholding was with the company and did not involve any open market trade. After the transaction, Winningham directly held 1,576,094 ordinary shares. He also had indirect holdings of 23,400 ordinary shares as custodian and 92,567 ordinary shares held by a trust.
Theravance Biopharma, Inc. executive Aziz Sawaf, SVP & Chief Financial Officer, reported a tax-related share disposition. On February 20, 2026, 20,672 Ordinary Shares were withheld at $19.66 per share to satisfy tax obligations from vesting restricted stock units. This withholding was conducted with the company and did not involve any open market trade. After this transaction, Sawaf directly held 316,123 Ordinary Shares.
Theravance Biopharma, Inc. senior vice president Aine Miller reported a tax-related share disposition linked to vesting equity awards. On the transaction date, 16,851 Ordinary Shares were withheld at a price of $19.66 per share to cover tax obligations from previously granted restricted stock units vesting. The shares were withheld by the company rather than sold in the open market, and Miller’s directly owned stake after this tax-withholding transaction was 184,161 Ordinary Shares.
Theravance Biopharma SVP Brett A. Grimaud reported a tax-related share disposition. On this Form 4, 20,833 Ordinary Shares were withheld at $19.66 per share to cover tax obligations from vesting restricted stock units. This was a transaction with the company, not an open-market trade, and left him holding 334,449 shares directly.
Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a tax-related share disposition connected to the vesting of restricted stock units. On this Form 4, 13,929 ordinary shares were withheld at a price of $19.66 per share to satisfy tax obligations, in a transaction with the issuer rather than through the open market. Following this tax-withholding event, Farnum directly owned 263,766 ordinary shares.
Theravance Biopharma, Inc. (TBPH) reported an insider equity transaction by its SVP & Chief Financial Officer on 11/20/2025. The officer had 18,627 ordinary shares withheld at a price of $17.90 per share in a transaction coded "F," which indicates shares were withheld to cover tax obligations from the vesting of previously granted restricted stock units.
After this tax-withholding event, the officer directly beneficially owned 336,795 ordinary shares. The explanation clarifies that this was a share withholding with the issuer and did not involve an open market transaction.
Theravance Biopharma, Inc. (TBPH) reported an insider equity transaction by a senior executive. The reporting person, identified as an officer with the title "SVP, DEV & HEAD OF IRE OFFICE," filed a Form 4 for activity dated 11/20/2025.
The filing shows that 6,989 ordinary shares were withheld and disposed of at a price of $17.90 per share in a transaction coded "F," which indicates shares were withheld to cover tax obligations from vesting restricted stock units. After this tax withholding, the reporting person beneficially owns 201,012 ordinary shares, held directly.
An explanation clarifies that the share withholding was with the issuer and did not involve an open market transaction. The form is filed for one reporting person and is signed by an attorney-in-fact on 11/24/2025.
Theravance Biopharma, Inc. officer reports tax-related share withholding. A senior vice president who is also general counsel and secretary reported that on 11/20/2025, 19,024 ordinary shares were withheld at a price of $17.9 per share. These shares were retained by the company to cover tax obligations from the vesting of previously granted restricted stock units, and the event did not involve any open market transactions. After this withholding, the officer beneficially owns 355,282 ordinary shares directly.
Theravance Biopharma, Inc. reported an insider equity transaction by a senior officer. On 11/20/2025, 9,060 ordinary shares were withheld at $17.90 per share to cover tax obligations from the vesting of previously granted restricted stock units. The explanation states that this share withholding was with the issuer and did not involve any open market transaction. Following this tax-related transaction, the officer directly beneficially owns 308,762 ordinary shares of Theravance Biopharma.
Theravance Biopharma, Inc. (TBPH) reported insider share movements by its Chief Executive Officer, who is also a director. On 11/19/2025, the reporting person made a gift of 9,900 ordinary shares and transferred the same number of shares into a custodial account under the Uniform Transfers to Minors Act, where the person serves as custodian and disclaims beneficial ownership of the grandchildren's shares. After this, 23,400 shares were held indirectly in the custodial account.
On 11/20/2025, 56,817 ordinary shares were withheld at a price of $17.9 per share to satisfy tax obligations from vesting restricted stock units in a transaction with the issuer. Following these transactions, the reporting person held 1,651,069 ordinary shares directly and 92,567 ordinary shares indirectly through a trust, in addition to the UTMA custodial holdings.
Theravance Biopharma (TBPH) filed a Form 4/A amending an insider transaction by a director under a Rule 10b5-1 plan adopted March 14, 2024. On 11/11/2025, the director sold 15,500 shares at $18.50 and 15,500 shares at $17. The filing also shows the exercise of 14,000 options at $10.15 and a same‑day sale of those 14,000 shares at $18.50. Following these transactions, beneficial ownership was 60,204 shares. The amendment corrects an earlier administrative error that had overstated one sale as 29,500 shares at $18.50.
Theravance Biopharma (TBPH) director reported insider transactions on Form 4. On 11/11/2025, the reporting person sold 29,500 Ordinary Shares at $18.5, 15,500 shares at $17, and sold 14,000 shares at $18.5 after exercising options at $10.15. These trades were made under a Rule 10b5-1 trading plan adopted on March 14, 2024.
Following the transactions, the reporting person beneficially owned 46,204 Ordinary Shares directly and held 107,878 derivative securities. The 14,000-share option was fully vested and exercisable per its original vesting terms.